At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CGTX Cognition Therapeutics, Inc
Trading 12-11 13:06:28 EST
1.70
+0.01
+0.53%
High1.71Low1.66Vol224.90K
Open1.70D1 Closing1.69Amplitude2.95%
Mkt Cap149.97MTradable Cap149.04MTotal Shares88.27M
T/O380.39KT/O Rate0.26%Tradable Shares87.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones  ·  12-04
Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewswire  ·  12-03
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease
Reuters  ·  12-01
Cognition Therapeutics Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (Ct1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (Ctad) Conference
THOMSON REUTERS  ·  12-01
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (Ct1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (Ctad) Conference
B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating
MT Newswires Live  ·  11-21
B. Riley Raises Price Target on Cognition Therapeutics to $3 From $2, Keeps Buy Rating
Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Dow Jones  ·  11-19
Cognition Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.
Cognition Therapeutics (CGTX) Receives a Buy from H.C. Wainwright
TIPRANKS  ·  11-19
Cognition Therapeutics (CGTX) Receives a Buy from H.C. Wainwright
Mesoblast Appoints James O'Brien CFO
MT Newswires Live  ·  11-17
Mesoblast Appoints James O'Brien CFO
BUZZ-Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division
Reuters  ·  11-17
BUZZ-Mesoblast's Australian shares climb as O'Brien becomes finance chief of US division
Cognition Therapeutics Completes Enrollment in Phase 2 Trial of Zervimesine for Early Alzheimer’s Disease
Reuters  ·  11-13
Cognition Therapeutics Completes Enrollment in Phase 2 Trial of Zervimesine for Early Alzheimer’s Disease
Cognition Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Reuters  ·  11-07
Cognition Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Cognition Therapeutics Q3 net loss narrows as trials ending lower R&D costs
Reuters  ·  11-06
Cognition Therapeutics Q3 net loss narrows as trials ending lower R&D costs
Cognition Therapeutics Q3 EPS $(0.06) Beats $(0.09) Estimate
Benzinga  ·  11-06
Cognition Therapeutics Q3 EPS $(0.06) Beats $(0.09) Estimate
Cognition Therapeutics reports Q3 cash position of $39.8 million and R&D expenses of $3.8 million
Reuters  ·  11-06
Cognition Therapeutics reports Q3 cash position of $39.8 million and R&D expenses of $3.8 million
Cognition Therapeutics Inc - Net Loss $0.06 per Share for Q3 2025
THOMSON REUTERS  ·  11-06
Cognition Therapeutics Inc - Net Loss $0.06 per Share for Q3 2025
Cognition Therapeutics Inc - Estimates Sufficient Cash to Fund Operations & Capital Expenditures Into Q2 of 2027
THOMSON REUTERS  ·  11-06
Cognition Therapeutics Inc - Estimates Sufficient Cash to Fund Operations & Capital Expenditures Into Q2 of 2027
Cognition Therapeutics Q3 Operating Expenses USD 6.375 Million
THOMSON REUTERS  ·  11-06
Cognition Therapeutics Q3 Operating Expenses USD 6.375 Million
Press Release: Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
Dow Jones  ·  11-06
Press Release: Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs
Cognition Therapeutics Advances Zervimesine to Phase 3 Trials
TIPRANKS  ·  09-15
Cognition Therapeutics Advances Zervimesine to Phase 3 Trials
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target
GlobeNewswire  ·  09-03
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

Introduction

Company Name.
Cognition Therapeutics, Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Issue price:
--